STOK

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Burstein JenniferDirector --17.8k shares Grant / ExerciseJun 3, 2026 $524.0K17.8k shares $29.46 $31.45
Harrison Seth LoringDirector --17.8k shares Grant / ExerciseJun 3, 2026 $524.0K17.8k shares $29.46 $31.45
Kaye Edward M. MDDirector --17.8k shares Grant / ExerciseJun 3, 2026 $524.0K17.8k shares $29.46 $31.45
Krainer Adrian R.Director --17.8k shares Grant / ExerciseJun 3, 2026 $524.0K17.8k shares $29.46 $31.45
Levin Arthur ADirector --17.8k shares Grant / ExerciseJun 3, 2026 $524.0K17.8k shares $29.46 $31.45
Smith JulieDirector --17.8k shares Grant / ExerciseJun 3, 2026 $524.0K17.8k shares $29.46 $31.45

News

seekingalpha.comStoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8

zacks.com4 Biotech Stocks Investors Should Watch in 2026zacks.comJun 5

zacks.comStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?zacks.comJun 4

businesswire.comStoke Therapeutics to Present at Upcoming Investor Conferences in Junebusinesswire.comMay 28

zacks.comIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?zacks.comMay 21

Trade STOK

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

CEO: Ian F. Smith
IPO Date: Jun 19, 2019

Market Data

Open: $29.45
High: $30.06
Low: $28.57
Volume: 362.6K
52W High: $40.22
52W Low: $11.12

Valuation

Market Cap: $1.8B
Enterprise Value: $1.7B

Financials

Free Cash Flow: $45M
Revenue: $184M
Net Income: $-6.9M
Cash: $84M
Debt: $0

Events

EarningsAug 11

EPS est. -0.73